Download scoring documents for this measure. BACK PROMIS SF v1.0-Dyspnea-Severity 5a Scoring Downloads http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions

Download this measure in English. BACK PROMIS Pool v1.0 - Dyspnea Emotional Response English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FANLTC Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FACT-Hep Scoring Downloads Download DOC

FACIT-COST COST: A FACIT Measure of Financial Toxicity For financial toxicity LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Developed in conjunction with the University of Chicago, the COST is a patient-reported outcome measure that describes the financial distress experienced by cancer patients. Since its initial publication, an additional item from the FACIT System has been included to screen for financial toxicity and to provide a good global summary item for financial toxicity. MEASURE NAME: COST: A FACIT Measure of Financial Toxicity (FACIT-COST) VERSION: 2 NUMBER OF ITEMS: 12 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Financial Toxicity TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FACT-GP DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the COST can be obtained by registering for permission. Users are not permitted to translate the COST without permission from FACIT.org. Permission from FACIT.org to translate the COST may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References de Souza J.A., Yap B.J., Wroblewski K., Blinder V., Araújo F.S., Hlubocky F.J., Nicholas L.H., O'Connor J.M., Brockstein B., Ratain M.J., Daugherty C.K., Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7. PMID: 27716900; PMCID: PMC5298039. Ezeife D.A., Morganstein B.J., Lau S., Law J.H., Le L.W., Bredle J., Cella D., Doherty M.K., Bradbury P., Liu G., Sacher A., Shepherd F.A., Leighl N.B. Financial Burden Among Patients with Lung Cancer in a Publically Funded Health Care System. Clin Lung Cancer 2019 Jul;20(4):231-236. doi: 10.1016/j.cllc.2018.12.010. Epub 2018 Dec 22. PMID: 30797721. Hlubocky F.J. et al. Financial Toxicity Has Never Been More Important in Cancer Care: How Do We Measure It?. JCO Oncol Pract 21, 52-56(2025). DOI:10.1200/OP.24.00162 Huntington S.F., Weiss B.M., Vogl D.T., Cohen A.D., Garfall A.L., Mangan P.A., Doshi J.A., Stadtmauer E.A. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015 Oct;2(10):e408-16. doi: 10.1016/S2352-3026(15)00151-9. Epub 2015 Sep 17. PMID: 26686042. Pangestu, S., Purba, F.D., Setyowibowo, H. et al. Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity. Health Qual Life Outcomes 22, 89 (2024). https://doi.org/10.1186/s12955-024-02303-5. Pangestu, S. et al. Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis. Value in Health , Volume 26, Issue 2, 300–316, February 2023. https://doi.org/10.1016/j.jval.2022.07.017. Patel, M.R., Troost, J.P., Heisler, M. et al. Clinically meaningful classes of financial toxicity for patients with diabetes. J Patient Rep Outcomes 9, 2 (2025). https://doi.org/10.1186/s41687-024-00834-5. Patel MR, Zhang G, Heisler M, Song PXK, Piette JD, Shi X, Choe HM, Smith A, Resnicow K. Measurement and validation of the Comprehensive Score for financial toxicity (COST) in a population with diabetes. Diabetes Care, 2022. Pitis A, Diamantopoulou M, Panagiotou A, Papageorgiou D, Tzavella F. Financial Toxicity and Its Association with the Quality of Life of Greek Patients with Cancer: A Cross-Sectional Study. Nurs Rep. 2025 Feb 13;15(2):67. doi: 10.3390/nursrep15020067. PMID: 39997803; PMCID: PMC11858100. Sadigh, G., Switchenko, J., Weaver, K.E. et al. Correlates of financial toxicity in adult cancer patients and their informal caregivers. Support Care Cancer (2021). https://doi.org/10.1007/s00520-021-06424-1. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE FACT-GP Functional Assessment of Cancer Therapy - General Population LEARN MORE

Download this measure in English. BACK FACT-B+4 English Downloads Download PDF Download DOC

Download this measure in English. BACK FACT-An English Downloads Download PDF Download DOC

View all available languages for this measure. BACK NFKSI-19 Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

Download this measure in English. BACK NVMBQ English Downloads Download PDF - Patient Download DOC - Patient Download PDF - Provider Download DOC - Provider

Download this measure in English. BACK PROMIS SF v1.0-Dyspnea-Severity 5a English Downloads Download PDF Download DOC

NVMBQ Nausea and Vomiting Management Barriers Questionnaire For cancer patients with chemotherapy-induced nausea and vomiting LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the NVMBQ measure: MEASURE NAME: Nausea and Vomiting Management Barriers Questionnaire (NVMBQ) VERSION: 1 NUMBER OF ITEMS: Patient version: 42; Provider version: 31 PATIENT POPULATION: Cancer patients 18 and older experiencing chemotherapy-induced nausea and vomiting RECALL PERIOD: None RESPONSE SCALE: 4 point scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: 15-20 minutes SCORING: None RELATED MEASURES: FACIT-AD , FAIT-F , FACIT-D DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NVMBQ can be obtained by registering for permission. Users are not permitted to translate the NVMBQ without permission from FACIT.org. Permission from FACIT.org to translate the NVMBQ may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Haselmayer D, Salsman JM, Cella D, Koller A. Psychometric Evaluation of the Patient-Related Nausea and Vomiting Management Barriers Questionnaire. J Pain Symptom Manage . 2020 Aug;60(2):439-448. doi: 10.1016/j.jpainsymman.2020.03.032. Epub 2020 Apr 8. PMID: 32276096. LICENSE THIS MEASURE Related Measures Related Measures FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE FAIT-F Functional Assessment of Incontinence Therapy – Fecal LEARN MORE FACIT-D Functional Assessment of Chronic Illness Therapy - Diarrhea LEARN MORE

Download this measure in English. BACK FACIT-TS-G English Downloads Download PDF Download DOC